Breast Cancer Research and Treatment

, Volume 107, Issue 3, pp 421–425

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk

  • Yong Zhu
  • Richard G. Stevens
  • Derek Leaderer
  • Aaron Hoffman
  • Theodore Holford
  • Yawei Zhang
  • Heather N. Brown
  • Tongzhang Zheng
Epidemiology

DOI: 10.1007/s10549-007-9565-0

Cite this article as:
Zhu, Y., Stevens, R.G., Leaderer, D. et al. Breast Cancer Res Treat (2008) 107: 421. doi:10.1007/s10549-007-9565-0

Abstract

Three known non-synonymous polymorphisms (Ala394Thr, Ser471Leu and Pro690Ala) in the largest circadian gene, Neuronal PAS domain protein 2 (NPAS2), were genotyped in a breast cancer case-control study conducted in Connecticut, USA (431 cases and 476 controls). We found that women with the heterozygous Ala394Thr genotype were significantly associated with breast cancer risk compared to those with the common homozygous Ala394Ala (OR = 0.61, 0.46–0.81, P = 0.001). This is the first evidence demonstrating a role of the circadian gene NPAS2 in human breast cancer, suggesting that genetic variations in circadian genes might be a novel panel of biomarkers for breast cancer risk.

Keywords

Circadian geneNPAS2Breast cancer

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Yong Zhu
    • 1
  • Richard G. Stevens
    • 2
  • Derek Leaderer
    • 1
  • Aaron Hoffman
    • 1
  • Theodore Holford
    • 1
  • Yawei Zhang
    • 1
  • Heather N. Brown
    • 1
  • Tongzhang Zheng
    • 1
  1. 1.Department of Epidemiology and Public HealthYale University School of MedicineNew HavenUSA
  2. 2.University of Connecticut Health CenterFarmingtonUSA